You are here: Home » Markets » News
Business Standard

Pharma shares in limelight on Fitch rating

SI Reporter  |  Mumbai 

Shares of pharmaceutical companies are in limelight in otherwise subdued market in morning trades after a global rating agency Fitch said its outlook on India's pharmaceutical sector for 2012 remains stable, as earnings prospects are expected to remain positive because of the growing global demand for generics and opportunities provided by patent expiries in developed .

Wockhardt, Orchid Chemcials, Biocon, Aurobindo Pharma, Ranbaxy Laboratories, Cipla, Sun Pharma and Dr Reddy’s Laboratories are trading higher by 2-5% on the Bombay Stock Exchange (BSE).

The BSE healthcare index of pharma companies has rallied 71 points or 1.1% compared with a marginal 10 points fall in the benchmark index Sensex at 1043 hours.

In a new report, Fitch points to forecasts from IMS Health which expects that the shift in global drug spending towards generics will rise to 39% of total pharmaceutical expenditures in 2015, compared to 20% in 2005 and 27% in 2010.

This growing demand, a subsequent increase in capacity utilisation and better cost rationalisation will ensure stability for Indian pharmaceutical companies' operating margins, and they could also benefit from additional licensing income from strategic alliances and the depreciating rupee, says the ratings agency.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Fri, February 03 2012. 11:30 IST